精准免疫分期指导慢性HBV感染者尽早启动抗病毒治疗  

Precise immunological classification guidance for early initiation of antiviral therapy in patients with chronic HBV infection

作　　者：赵素贤[1] 常楚笛 南月敏[1] Zhao Suxian;Chang Chudi;Nan Yuemin(Department of Traditional and Western Medical Hepatology,the Third Hospital of Hebei Medical University,the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province,Shijiazhuang 050051,China)

机构地区：[1]河北医科大学第三医院中西医结合肝病科、河北省慢性肝病肝纤维化研究重点实验室,石家庄050051

出　　处：《中华肝脏病杂志》2023年第3期228-232,共5页Chinese Journal of Hepatology

摘　　要：慢性乙型肝炎病毒(HBV)感染是影响世界公共卫生的重大问题,合理抗病毒治疗可阻止或延缓肝硬化、肝癌的发生。精准免疫学分期有助于对HBV感染者制定个体化的治疗与管理方案,符合抗病毒指征者尽早启动抗病毒治疗,并依据抗病毒治疗应答情况优化核苷(酸)类似物治疗方案或联合聚乙二醇干扰素α,以最大限度实现病毒学和血清学应答,提高临床治愈率,改善长期预后。Chronic hepatitis B virus(HBV)infection is a major problem affecting global public health.Appropriate antiviral therapy use can prevent or delay the occurrence of liver cirrhosis and liver cancer.Precise immunological classification can be helpful to formulate personalized therapy and management plans for HBV-infected patients.Antiviral therapy should be started early in those who meet antiviral indications,and nucleos(t)ide analogue therapeutic regimens alone or in combination with pegylated interferon alpha should be optimized according to antiviral therapy response,in order to maximize the realization of virological and serological response,improve clinical cure rate,and enhance long-term prognosis.

关 键 词：乙型肝炎病毒 感染 免疫学 分期 抗病毒治疗 

分 类 号：R512.62[医药卫生—内科学]